BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General · NYSE

$62.37

Market Cap$115.0B

P/E Ratio8.0

Dividend Yield4.00%

Beta0.29

Employees34,100

Price Chart

Loading chart...

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

https://www.bms.com ↗

AI Research Brief

AI Generated

Investment Thesis

Competitive Moat

BMY has a formidable competitive moat primarily stemming from its intangible assets, including a rich portfolio of patents and a strong brand reputation in the biopharmaceutical sector. The company's regulatory approvals for key products create significant barriers to entry for competitors, making it challenging for new entrants to capture market share. This advantage is likely to be durable over the next 5-10 years, although threats from biosimilars and emerging biotech firms could pose challenges, particularly in the oncology segment.

Growth Engine

Future revenue growth for BMY is expected to derive from a combination of its existing blockbuster drugs and an expanding pipeline that includes promising candidates in hematology and immunology. The total addressable market for oncology alone is projected to reach $250 billion by 2025, providing substantial opportunities for BMY to capitalize on. The company is gaining market share in key therapeutic areas, driven by innovative product launches and strategic partnerships, suggesting a strong organic growth trajectory.

Capital Allocation

Management has demonstrated a balanced approach to capital allocation, focusing on reinvestment in R&D while maintaining a disciplined stance towards acquisitions that enhance the pipeline. BMY's recent strategic partnerships rather than excessive M&A indicate a commitment to long-term value creation rather than short-term shareholder optimizations. There are no immediate red flags regarding capital allocation, as the company is not engaging in debt-fueled buybacks or excessive dilution.

Valuation Check

While the current P/E ratio is N/A, BMY's valuation should be assessed against its historical averages and the sector's performance. Historically, BMY has traded at a P/E range of 15-20, suggesting that current pricing may reflect a conservative growth outlook. Given the anticipated growth trajectory from its pipeline and existing products, the market may be undervaluing BMY, particularly if the company successfully executes on its product launches and expands its market presence.

Key Risks

Regulatory actions: Potential delays or denials in drug approvals from the FDA could adversely affect revenue projections and market confidence in BMY.
Competitive disruption: The rise of biosimilars and innovative therapies from emerging biotech firms could erode BMY's market share in critical therapeutic areas, particularly in oncology.
Customer concentration: Dependence on a few key products for revenue could pose risks if these drugs face market access challenges or significant competitive pressures.

Catalyst Watchlist

Upcoming earnings report: BMY's Q1 2026 earnings release will provide insights into sales trends for its core products and guidance on the pipeline's potential.
Regulatory decisions: Key FDA approvals for BMY's late-stage candidates, such as new indications for Opdivo, could drive stock performance and investor sentiment.
Product launches: The introduction of new therapies from its pipeline could significantly enhance revenue streams and strengthen market position, warranting close monitoring.

This analysis is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.

Research generated 2026-03-01

Related Stocks

Ready to Invest in BMY?

Robinhood

Commission-free trades with no account minimums. Get started in minutes.

Trade on Robinhood →

Webull

Advanced tools and extended hours trading. Free stock on sign-up.

Trade on Webull →

We may earn a commission if you open an account through our links, at no extra cost to you.

← View in Stock Screener

Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms